Special Alerts:

Roche and FDA informed healthcare professionals of neuropsychiatric events associated with the use of oseltamivir (Tamiflu), in patients with influenza. These symptoms, as described in post marketing reports mostly from Japan, include delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated. For more information visit the FDA website at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tamiflu, http://www.fda.gov/medwatch/safety/2008/Tamiflu_DHCP.pdf and http://www.fda.gov/medwatch/safety/2008/Tamiflu_PI.pdf.